Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Clinical Study of Eculizumab (h5G1.1-mAb) in Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients: Extension Study to C07-001 Protocol

NCT01194804 is registered in ClinicalTrials.gov with Alexion Pharmaceuticals, Inc. as lead sponsor.

NCT NCT01194804
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01194804 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Clinical Study of Eculizumab (h5G1.1-mAb) in Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients: Extension Study to C07-001 Protocol
Lead sponsor
Alexion Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2008
Completion date
March 31, 2011
Enrollment
27 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

paroxysmal nocturnal hemoglobinuria